Dravet Syndrome Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, and others

December 14 20:50 2022
Dravet Syndrome Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, and others
The Dravet Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dravet Syndrome pipeline products will significantly revolutionize the Dravet Syndrome market dynamics.

DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Dravet Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


To Know in detail about the Dravet Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dravet Syndrome Market Insights


Dravet Syndrome Overview

According to National Organization for Rare Disorders (NORD), Dravet Syndrome (DS) is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.


Some of the key facts of the Dravet Syndrome Market Report: 

  • The Dravet Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Dravet Syndrome is a severe infantile onset epileptic encephalopathy associated with mutations in the sodium channel alpha 1 subunit gene SCN1A in about 80-90% of cases. 90% of mutations appear to be de novo and not inherited from a parent
  • According to a study published by Wu et. al., incidence of Dravet Syndrome in the US Population is 1:15,700, 80% of whom have a mutation in their SCN1A gene
  • Key Dravet Syndrome Companies: Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, and others
  • Key Dravet Syndrome Therapies: Soticlestat, Larcaserin, STK-001, EPX-100, and others
  • Dravet Syndrome epidemiology based on gender analyzed that more men than women have Dravet Syndrome


Get a Free sample for the Dravet Syndrome Market Report- 



Key benefits of the Dravet Syndrome Market report:

  1. Dravet Syndrome market report covers a descriptive overview and comprehensive insight of the Dravet Syndrome Epidemiology and Dravet Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Dravet Syndrome market report provides insights on the current and emerging therapies.
  3. Dravet Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Dravet Syndrome market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Dravet Syndrome market.


Download the report to understand which factors are driving Dravet Syndrome epidemiology trends @ Dravet Syndrome Epidemiological Insights


Dravet Syndrome Market  

The dynamics of the Dravet Syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“Of the emerging therapies several molecules are in late clinical stage as Soticlestat, Lorcaserin etc.”


Dravet Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


Dravet Syndrome Epidemiology Segmentation:

The Dravet Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Dravet Syndrome
  • Prevalent Cases of Dravet Syndrome by severity
  • Gender-specific Prevalence of Dravet Syndrome
  • Diagnosed Cases of Episodic and Chronic Dravet Syndrome


Dravet Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dravet Syndrome market or expected to get launched during the study period. The analysis covers Dravet Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dravet Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Discover more about therapies set to grab major Dravet Syndrome market share @ Dravet Syndrome market forecast 


Dravet Syndrome Therapies and Key Companies

  • Soticlestat: Takeda
  • Larcaserin: Eisai
  • STK-001: Stoke Therapeurtics
  • EPX-100: EpyGenix Therapeutics


Dravet Syndrome Market Drivers

  • The researchers are undergoing advancement in already approved drugs by providing an alternative means of delivering the drug
  • A broader awareness among health care providers and the public for better treatments helps to improve care and outcomes


Scope of the Dravet Syndrome Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Dravet Syndrome Companies: Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, and others
  • Key Dravet Syndrome Therapies: Soticlestat, Larcaserin, STK-001, EPX-100, and others
  • Dravet Syndrome Therapeutic Assessment: Dravet Syndrome current marketed and Dravet Syndrome emerging therapies
  • Dravet Syndrome Market Dynamics: Dravet Syndrome market drivers and Dravet Syndrome market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Dravet Syndrome Unmet Needs, KOL’s views, Analyst’s views, Dravet Syndrome Market Access and Reimbursement 


Dravet Syndrome Market Barriers

  • There are no new novel drugs approved by the regulatory authorities for this condition in the past few years
  • The researchers are mainly focused on the specific treatment of DS Impairment associated with Schizophrenia, despite symptomatic treatment as it is the major unmet need
  • One of the challenges is a very long duration of untreated illness or untreated psychosis


Table of Contents 

1. Dravet Syndrome Market Report Introduction

2. Executive Summary for Dravet Syndrome

3. SWOT analysis of Dravet Syndrome

4. Dravet Syndrome Patient Share (%) Overview at a Glance

5. Dravet Syndrome Market Overview at a Glance

6. Dravet Syndrome Disease Background and Overview

7. Dravet Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Dravet Syndrome 

9. Dravet Syndrome Current Treatment and Medical Practices

10. Dravet Syndrome Unmet Needs

11. Dravet Syndrome Emerging Therapies

12. Dravet Syndrome Market Outlook

13. Country-Wise Dravet Syndrome Market Analysis (2019–2032)

14. Dravet Syndrome Market Access and Reimbursement of Therapies

15. Dravet Syndrome Market Drivers

16. Dravet Syndrome Market Barriers

17.  Dravet Syndrome Appendix

18. Dravet Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


To know more about Dravet Syndrome treatment, visit @ Dravet Syndrome Medications

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting